FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of
FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
This study is designed to assess the potential anti-tumor activity when administered at the
100mg QD of FLX475 with pembrolizumab and will be conducted (2) cohorts as detailed below.
- Cohort 1: EBV negative / CPI naïve gastric cancer subjects who have progressed on at
least 2 prior systemic treatments for advanced or metastatic gastric cancer
- Cohort 2: EBV positive / CPI naïve gastric cancer subjects who had at least 1 prior
systemic treatment for advanced or metastatic gastric cancer
Approximately 90 subjects may be enrolled across two cohorts to examine the safety and
efficacy.